Page last updated: 2024-12-05

thiophene-2-carboxylate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Thiophene-2-carboxylate is a heterocyclic compound that serves as a versatile building block in organic synthesis. It is often used as a precursor to other thiophene-based compounds, which are known for their applications in various fields, including pharmaceuticals, agrochemicals, and materials science. The compound's synthesis involves the reaction of thiophene with carbon dioxide or carbon monoxide in the presence of a suitable catalyst. Thiophene-2-carboxylate's importance lies in its ability to incorporate the thiophene ring into complex molecules, enhancing their properties, such as optical, electronic, and biological activities. Research focuses on exploring its potential applications, including the development of novel drugs, functional materials, and synthetic methods.'
```

thiophene-2-carboxylic acid : A thiophenecarboxylic acid in which the carboxy group is located at position 2. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID10700
CHEMBL ID1222314
CHEBI ID71241
SCHEMBL ID83000
MeSH IDM0047338

Synonyms (71)

Synonym
BIDD:GT0592
unii-3fd00jx53j
5-18-06-00158 (beilstein handbook reference)
3fd00jx53j ,
CHEMBL1222314 ,
thiophene carboxylic acid
chebi:71241 ,
2-thiophenecarboxylic acid
2-tca
nsc2188
2-thiophenic acid
2-thenoic acid
2-carboxythiophene
527-72-0
.alpha.-thiophenecarboxylic acid
nsc-2188
NCIOPEN2_000991
thiophenecarboxylic acid
thiophene-2-carboxylic acid
STK362877
2-thiophenecarboxylic acid, reagentplus(r), 99%
2HDQ
c5h4o2s
einecs 208-423-4
ai3-16118
brn 0110150
alpha-thiophenecarboxylic acid
nsc 2188
2-thienylcarboxylic acid
AC-4922
rhinotrophyl (tn)
tenoic acid (dcf)
thiophene-2-carbixylic acid
D08568
T0218
AKOS000119344
NCGC00188253-01
BMSE000848
bdbm50324678
A829248
tenoic acid
thiolcarboxylic acid
BP-20572
FT-0632301
AM20100294
SCHEMBL83000
2-thiophenecarboxylic acid [mi]
thenoic acid
thenoic acid [who-dd]
DTXSID2060177
2-thienoic acid
thienyl carboxylic acid
thiophencarboxylic acid
thiopene-2-carboxylic acid
thiophen-2-carboxylic acid
thienoic acid
2-thiophene-carboxylic acid
2-thiophene carboxylic acid
2-thiophenecarboxylicacid
W-105797
BS-3764
CS-W020070
mfcd00005437
F2191-0071
D70571
2-thiophenecarboxylic acid, vetec(tm) reagent grade, 98%
thiophene-2-carboxylicacid
SY001476
Q2823319
BCP15028
EN300-16724

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" While it has been possible to develop nNOS selective aminopyridine inhibitors, many of the most potent and selective inhibitors exhibit poor bioavailability properties."( Structural Basis for Isoform Selective Nitric Oxide Synthase Inhibition by Thiophene-2-carboximidamides.
Chreifi, G; Evenson, RJ; Li, H; Poulos, TL; Silverman, RB, 2018
)
0.48

Dosage Studied

ExcerptRelevanceReference
" A single dose of each compound was administered orally, or intraperitoneally, while multiple oral dosing was carried out once daily for a week."( [Effect of azosemide (SK-110) and its metabolites on mouse liver].
Asaeda, N; Haruyama, K; Ikawa, E; Koide, M; Shinoda, M; Tagawa, Y; Tamano, S, 1984
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
thiophenecarboxylic acid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Smad3Homo sapiens (human)Potency6.30960.00527.809829.0929AID588855
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Ki40,000.000019,000.000029,500.000040,000.0000AID977610
Chain A, Beta-lactamaseEscherichia coli K-12Ki40,000.000019,000.000029,500.000040,000.0000AID977610
Chain A, Beta-lactamaseEscherichia coli K-12Ki40,000.00005.000019,668.333340,000.0000AID977610
Chain A, Beta-lactamaseEscherichia coli K-12Ki40,000.000019,000.000029,500.000040,000.0000AID977610
Beta-lactamaseEscherichia coli K-12Ki40,000.00000.02703.64137.3000AID500280
D-amino-acid oxidaseHomo sapiens (human)IC50 (µMol)7.80000.00401.119910.0000AID1422158
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (10)

Processvia Protein(s)Taxonomy
antibiotic catabolic processBeta-lactamaseEscherichia coli K-12
response to antibioticBeta-lactamaseEscherichia coli K-12
proline catabolic processD-amino-acid oxidaseHomo sapiens (human)
digestionD-amino-acid oxidaseHomo sapiens (human)
D-amino acid catabolic processD-amino-acid oxidaseHomo sapiens (human)
D-serine catabolic processD-amino-acid oxidaseHomo sapiens (human)
dopamine biosynthetic processD-amino-acid oxidaseHomo sapiens (human)
D-alanine catabolic processD-amino-acid oxidaseHomo sapiens (human)
D-serine metabolic processD-amino-acid oxidaseHomo sapiens (human)
neutrophil-mediated killing of gram-negative bacteriumD-amino-acid oxidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
beta-lactamase activityBeta-lactamaseEscherichia coli K-12
hydrolase activityBeta-lactamaseEscherichia coli K-12
D-amino-acid oxidase activityD-amino-acid oxidaseHomo sapiens (human)
protein bindingD-amino-acid oxidaseHomo sapiens (human)
identical protein bindingD-amino-acid oxidaseHomo sapiens (human)
FAD bindingD-amino-acid oxidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
outer membrane-bounded periplasmic spaceBeta-lactamaseEscherichia coli K-12
periplasmic spaceBeta-lactamaseEscherichia coli K-12
mitochondrial outer membraneD-amino-acid oxidaseHomo sapiens (human)
extracellular regionD-amino-acid oxidaseHomo sapiens (human)
cytoplasmD-amino-acid oxidaseHomo sapiens (human)
peroxisomal matrixD-amino-acid oxidaseHomo sapiens (human)
cytosolD-amino-acid oxidaseHomo sapiens (human)
cell projectionD-amino-acid oxidaseHomo sapiens (human)
presynaptic active zoneD-amino-acid oxidaseHomo sapiens (human)
cytoplasmD-amino-acid oxidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (41)

Assay IDTitleYearJournalArticle
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID500280Inhibition of Escherichia coli AmpC assessed as nitrocefin hydrolysis by UV-Vis spectrophotometry2006Nature chemical biology, Dec, Volume: 2, Issue:12
Deconstructing fragment-based inhibitor discovery.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID573106Cytotoxicity against human Huh-9-13 cells after 3 days by MTT assay2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID573854Antiviral activity against Hepatitis C virus GT-1a harboring NS5B polymerase C316Y mutant gene2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID573107Cytotoxicity against human Huh-Mono cells after 3 days by MTT assay2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID573853Antiviral activity against Hepatitis C virus GT-1a harboring NS5B polymerase M414T mutant gene2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID573112Cytotoxicity against human Huh5-2 cells after 3 days by MTT assay2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID573858Antiviral activity against Hepatitis C virus GT-1b harboring wild type NS5B polymerase2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796.
AID1530048Inhibition of Streptococcus pyogenes SrtA deltaN81 mutant expressed in Escherichia coli BL21(DE3) at 100 uM using Abz-LPETA-Dap(Dnp) as substrate preincubated for 10 mins followed by substrate addition measured every min for 2.5 hrs by fluorimetric assay 2019European journal of medicinal chemistry, Jan-01, Volume: 161Identification of potential antivirulence agents by substitution-oriented screening for inhibitors of Streptococcus pyogenes sortase A.
AID573855Antiviral activity against Hepatitis C virus GT-1a harboring NS5B polymerase C316Y/L392F mutant gene2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID573108Antiviral activity against Hepatitis C virus genotype 1b infected in human Huh5-2 cells assessed as reduction in replicon RNA after 4 days by luciferase assay2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID573852Antiviral activity against Hepatitis C virus GT-1a harboring NS5B polymerase L392F mutant gene2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796.
AID573111Antiviral activity against Hepatitis C virus genotype 1b infected in human Huh-Mono cells assessed as reduction in replicon RNA after 4 days by RT-qPCR analysis2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID573859Antiviral activity against Hepatitis C virus GT-1a harboring wild type NS5B polymerase2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796.
AID573109Antiviral activity against Hepatitis C virus genotype 1b infected in human Huh-9-13 cells assessed as reduction in replicon RNA after 4days by RT-qPCR analysis2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID573856Antiviral activity against Hepatitis C virus GT-1a harboring NS5B polymerase C316Y/M414T mutant gene2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796.
AID573857Antiviral activity against Hepatitis C virus GT-1a harboring NS5B polymerase L392F/M414T mutant gene2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID573110Antiviral activity against Hepatitis C virus genotype 1b infected in human HuH6 cells assessed as reduction in replicon RNA after 4days by RT-qPCR analysis2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID573105Cytotoxicity against human HuH6 cells after 3 days by MTT assay2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1422158Inhibition of human DAO using D-serine as substrate after 20 mins in presence of FAD2018European journal of medicinal chemistry, Nov-05, Volume: 159Structural basis for potent inhibition of d-amino acid oxidase by thiophene carboxylic acids.
AID573851Antiviral activity against Hepatitis C virus GT-1b harboring NS5B polymerase C316Y mutant gene relative to wild type2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1811Experimentally measured binding affinity data derived from PDB2006Nature chemical biology, Dec, Volume: 2, Issue:12
Deconstructing fragment-based inhibitor discovery.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2006Nature chemical biology, Dec, Volume: 2, Issue:12
Deconstructing fragment-based inhibitor discovery.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (37)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (16.22)18.7374
1990's5 (13.51)18.2507
2000's13 (35.14)29.6817
2010's12 (32.43)24.3611
2020's1 (2.70)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.84 (24.57)
Research Supply Index3.74 (2.92)
Research Growth Index4.68 (4.65)
Search Engine Demand Index32.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (5.13%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other37 (94.87%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]